Credit Suisse’s CASI Pharmaceuticals CASI Stock Holding History

Credit Suisse’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,797	Closed	-$8K	–	4057
2022 Q2	$8K	Buy	+2,797	New	+$12.2K	﹤0.01%	3733
2021 Q1	–	Sell	-1,941	Closed	-$57K	–	4312
2020 Q4	$57K	Buy	+1,941	New	+$42.2K	﹤0.01%	4242
2019 Q4	–	Sell	-1,187	Closed	-$39K	–	4168
2019 Q3	$39K	Buy	+1,187	New	+$38.1K	﹤0.01%	4058
2019 Q2	–	Sell	-1,319	Closed	-$37K	–	4096
2019 Q1	$37K	Buy	+1,319	New	+$46K	﹤0.01%	3918
2018 Q3	–	Sell	-1,481	Closed	-$122K	–	3795
2018 Q2	$122K	Buy	+1,481	New	+$100K	﹤0.01%	3817

Other funds holding CASI

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Credit Suisse's CASI Position: Q3 2022 in Review

Credit Suisse sold out of CASI Pharmaceuticals (CASI) in Q3 2022, closing a stake of 2,797 shares — an estimated $8K sold.

Credit Suisse first reported a position in CASI in Q2 2018 and held it in 5 quarters. The position peaked at $122K in Q2 2018. 24 funds tracked by Wall St. Rank hold CASI as of Q3 2022.

Credit Suisse reported no remaining CASI Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 2,797 CASI Pharmaceuticals shares in Q3 2022, an estimated $8K.
Credit Suisse first reported a position in CASI Pharmaceuticals in Q2 2018 and held it in 5 quarters.
Credit Suisse's CASI Pharmaceuticals position peaked at $122K in Q2 2018.
24 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.